适应性深度大脑刺激与步行阶段相适应,改善了帕金森病患者的步行
Kenneth H Louie1, Jannine P Balakid1, Jessica E Bath1,2
1Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
medRxiv : the preprint server for health sciences
|September 2, 2025
概括
这项研究引入了对帕金森病 (PD) 的步态相同步适应性深度大脑刺激 (aDBS). 这种新的方法可以动态调整刺激以改善PD患者的步行控制和减少跌倒.
科学领域:
- 神经科学
- 生物医学工程
- 神经调节
背景情况:
- 步行功能障碍是帕金森病的主要障碍.
- 传统的深度大脑刺激 (DBS) 对于与PD相关的行走障碍通常具有有限的有效性.
- 需要先进的神经调节策略来解决PD的动态运动缺陷.
研究的目的:
- 开发和评估一种新的步态相同步自适应式DBS (aDBS) 范式.
- 研究使用个性化的神经生物标志物来指导实时神经调节的可行性.
- 评估aDBS在改善PD患者的步态指标和减少跌倒方面的有效性.
主要方法:
- 在五名PD参与者中,从皮质和状场潜力中确定了步行阶段的个性化神经生物标志物.
- 一个双向神经刺激器被编程为实时检测摆动阶段和次秒幅度调制.
- 在急性和多天交叉研究中,对DBS和临床优化的连续DBS进行了比较.
主要成果:
- 与连续的DBS相比,步态相同步的aDBS显著降低了步态变性和改善了双边对称性.
- 在多天的时间里,aDBS疗法得到了良好耐受,并保持了一般运动症状的控制.
- 使用aDBS的参与者减少了跌倒和其他步态的改善.
结论:
- 生物标志物驱动的运动同步神经调节对于PD是可行的.
- 步态相同步aDBS代表了恢复帕金森病的动态运动控制的有希望的策略.
- 这种适应性神经调节技术在治疗PD相关的步行功能障碍方面提供了潜在的进步.
更多相关视频
相关概念视频
Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702


